JP2019519246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519246A5 JP2019519246A5 JP2018569009A JP2018569009A JP2019519246A5 JP 2019519246 A5 JP2019519246 A5 JP 2019519246A5 JP 2018569009 A JP2018569009 A JP 2018569009A JP 2018569009 A JP2018569009 A JP 2018569009A JP 2019519246 A5 JP2019519246 A5 JP 2019519246A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- virus
- composition
- cell population
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 25
- 238000000034 method Methods 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 102000004127 Cytokines Human genes 0.000 claims 6
- 108090000695 Cytokines Proteins 0.000 claims 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 4
- 108090000172 Interleukin-15 Proteins 0.000 claims 4
- 108010002586 Interleukin-7 Proteins 0.000 claims 4
- 238000009169 immunotherapy Methods 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 101710120600 Cancer/testis antigen 1 Proteins 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000763 Survivin Human genes 0.000 claims 2
- 108010002687 Survivin Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 108010074108 interleukin-21 Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101150059079 EBNA1 gene Proteins 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 claims 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 101150113776 LMP1 gene Proteins 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 241000907316 Zika virus Species 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- -1 pp65 Proteins 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022031731A JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
| JP2024083379A JP2024103547A (ja) | 2016-06-28 | 2024-05-22 | 免疫療法向けのｔ細胞組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355533P | 2016-06-28 | 2016-06-28 | |
| US201662355506P | 2016-06-28 | 2016-06-28 | |
| US201662355458P | 2016-06-28 | 2016-06-28 | |
| US62/355,506 | 2016-06-28 | ||
| US62/355,458 | 2016-06-28 | ||
| US62/355,533 | 2016-06-28 | ||
| PCT/US2017/039846 WO2018005712A1 (en) | 2016-06-28 | 2017-06-28 | T cell compositions for immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031731A Division JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519246A JP2019519246A (ja) | 2019-07-11 |
| JP2019519246A5 true JP2019519246A5 (enExample) | 2020-08-06 |
| JP7034955B2 JP7034955B2 (ja) | 2022-03-14 |
Family
ID=60787739
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018569009A Active JP7034955B2 (ja) | 2016-06-28 | 2017-06-28 | 免疫療法向けのｔ細胞組成物 |
| JP2022031731A Pending JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
| JP2024083379A Pending JP2024103547A (ja) | 2016-06-28 | 2024-05-22 | 免疫療法向けのｔ細胞組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031731A Pending JP2022066355A (ja) | 2016-06-28 | 2022-03-02 | 免疫療法向けのｔ細胞組成物 |
| JP2024083379A Pending JP2024103547A (ja) | 2016-06-28 | 2024-05-22 | 免疫療法向けのｔ細胞組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20200237819A1 (enExample) |
| EP (1) | EP3487990A4 (enExample) |
| JP (3) | JP7034955B2 (enExample) |
| KR (1) | KR20190037243A (enExample) |
| CN (1) | CN109715788A (enExample) |
| AU (2) | AU2017290119A1 (enExample) |
| CA (1) | CA3068387A1 (enExample) |
| IL (1) | IL263896A (enExample) |
| MX (1) | MX2019000180A (enExample) |
| SG (1) | SG11201811745UA (enExample) |
| WO (1) | WO2018005712A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011028531A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| WO2013119947A1 (en) | 2012-02-09 | 2013-08-15 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| AU2016235388B2 (en) * | 2015-03-20 | 2022-02-03 | Children's National Medical Center | Generating virus or other antigen-specific T cells from a naive T cell population |
| DK3532607T3 (da) | 2016-10-26 | 2024-04-02 | Iovance Biotherapeutics Inc | Restimulation af kryokonserverede, tumorinfiltrerende lymfocytter |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| EP3541930A1 (en) | 2016-11-17 | 2019-09-25 | Iovance Biotherapeutics, Inc. | Remnant tumor infiltrating lymphocytes and methods of preparing and using the same |
| CA3049165A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| EP4053268B1 (en) | 2017-01-20 | 2025-10-08 | Kyoto University | Method for producing cd8alpha+beta+cytotoxic t cells |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| TW201930340A (zh) * | 2017-12-18 | 2019-08-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
| SG11202006541UA (en) | 2018-01-08 | 2020-08-28 | Iovance Biotherapeutics Inc | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JP7198602B2 (ja) * | 2018-07-11 | 2023-01-04 | カワサキモータース株式会社 | 自動二輪車 |
| WO2020027094A1 (ja) * | 2018-07-31 | 2020-02-06 | サイアス株式会社 | ｉＰＳ細胞を介して再生Ｔ細胞集団を製造する方法 |
| EP3830249A1 (en) * | 2018-07-31 | 2021-06-09 | polybliocept GmbH | Production and selection of tumor uber reactive immune cells (turics) |
| EP3834833A4 (en) * | 2018-08-10 | 2022-05-18 | Eutilex Co., Ltd. | Cancer antigen-specific cytotoxic t cells |
| WO2020032782A1 (ko) * | 2018-08-10 | 2020-02-13 | 주식회사 유틸렉스 | 암항원 특이적 cd8+ t 세포의 제조 및 동결보존 방법 |
| WO2020085480A1 (ja) * | 2018-10-26 | 2020-04-30 | キッセイ薬品工業株式会社 | 高効率な遺伝子改変細胞の作製方法 |
| EP3873500A4 (en) | 2018-10-31 | 2023-01-11 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| WO2020092736A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR20210091213A (ko) | 2018-11-05 | 2021-07-21 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도 |
| WO2020102701A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for the manufacture of th1/tc1 phenotype t cells |
| AU2019403263A1 (en) * | 2018-12-18 | 2021-07-01 | Beth Israel Deaconess Medical Center, Inc. | Generation of organoid-primed T (opT) cells with memory phenotype |
| CA3126066A1 (en) * | 2019-01-07 | 2020-07-16 | Children's National Medical Center | Ex vivo activated t-lymphocytic compositions and methods of using the same |
| BR112021015750A2 (pt) * | 2019-02-14 | 2021-10-26 | Research Institute At Nationwide Children's Hospital | Uso de um agente estimulante para testar a potência de células imunes |
| KR20210152515A (ko) | 2019-04-12 | 2021-12-15 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020243729A1 (en) * | 2019-05-31 | 2020-12-03 | Children's National Medical Center | Cytokine cocktails for selective expansion of t cell subsets |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| CN114615886A (zh) * | 2019-08-29 | 2022-06-10 | 得克萨斯大学体系董事会 | 细胞冷冻保存培养基 |
| US20230032934A1 (en) * | 2019-11-27 | 2023-02-02 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
| WO2021133667A1 (en) * | 2019-12-23 | 2021-07-01 | Baylor College Of Medicine | T cell performance assay as a prognostic factor for clinical outcome |
| US12378521B2 (en) | 2020-04-15 | 2025-08-05 | Amgen Inc. | Method for enhancing production of genetically engineered autologous T cells |
| US12241086B2 (en) | 2020-04-15 | 2025-03-04 | Amgen Inc. | Process for generating genetically engineered autologous T cells |
| KR20230125204A (ko) * | 2020-11-25 | 2023-08-29 | 지니우스 바이오테크놀로지 인코포레이티드 | 항원 특이적인 t 세포 및 이의 제조 및 이용 방법 |
| CN113481157B (zh) * | 2021-07-21 | 2023-03-17 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞的优化制备方法 |
| CN113564116B (zh) * | 2021-07-21 | 2023-08-01 | 北京赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ce的制备方法 |
| CN113512529B (zh) * | 2021-07-21 | 2022-11-25 | 上海赛傲生物技术有限公司 | 特异性抗病毒过继免疫细胞ab的制备方法 |
| US20250130220A1 (en) * | 2021-09-08 | 2025-04-24 | KSQ Therapeutics, Inc. | Lymphocyte potency assay |
| EP4412628A1 (en) * | 2021-10-08 | 2024-08-14 | Baylor College of Medicine | Targeting common somatic mutations in breast cancer with neo-antigen specific adoptive t cell therapy |
| JP2023064787A (ja) * | 2021-10-27 | 2023-05-12 | 国立大学法人京都大学 | Ｔ細胞の品質評価方法、および当該方法に用いる試薬 |
| US20250223552A1 (en) * | 2022-03-18 | 2025-07-10 | St. Jude Children's Research Hospital, Inc. | Method for preparing t cells for adoptive t cell therapy |
| EP4507704A1 (en) | 2022-04-15 | 2025-02-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69941150D1 (de) * | 1998-05-11 | 2009-09-03 | Miltenyi Biotec Gmbh | Verfahren zur direkten auswahl von antigen-spezifischen t-zellen |
| MXPA05001044A (es) | 2002-08-08 | 2005-06-22 | Baylor College Medicine | Aislamiento e identificacion de celulas t. |
| PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
| WO2011028531A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| WO2011146473A1 (en) * | 2010-05-17 | 2011-11-24 | Duke University | Methods of treatment using ex vivo expansion of cord blood t cells |
| EP2714072A1 (en) | 2011-05-26 | 2014-04-09 | Geneius Biotechnology Investments, LLC | Modulated immunodominance therapy |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| WO2016033690A1 (en) | 2014-09-04 | 2016-03-10 | Stemcell Technologies Inc. | Soluble antibody complexes for t cell or nk cell activation and expansion |
| EP3234130B1 (en) * | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Methods for profiling the t-cell- receptor repertoire |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
-
2017
- 2017-06-28 MX MX2019000180A patent/MX2019000180A/es unknown
- 2017-06-28 EP EP17821200.7A patent/EP3487990A4/en active Pending
- 2017-06-28 US US16/312,023 patent/US20200237819A1/en not_active Abandoned
- 2017-06-28 CA CA3068387A patent/CA3068387A1/en active Pending
- 2017-06-28 JP JP2018569009A patent/JP7034955B2/ja active Active
- 2017-06-28 CN CN201780053540.8A patent/CN109715788A/zh active Pending
- 2017-06-28 AU AU2017290119A patent/AU2017290119A1/en not_active Abandoned
- 2017-06-28 KR KR1020197002828A patent/KR20190037243A/ko not_active Ceased
- 2017-06-28 SG SG11201811745UA patent/SG11201811745UA/en unknown
- 2017-06-28 WO PCT/US2017/039846 patent/WO2018005712A1/en not_active Ceased
-
2018
- 2018-12-23 IL IL263896A patent/IL263896A/en unknown
-
2022
- 2022-03-02 JP JP2022031731A patent/JP2022066355A/ja active Pending
- 2022-06-16 US US17/807,213 patent/US20230145991A1/en active Pending
-
2023
- 2023-10-26 AU AU2023254998A patent/AU2023254998A1/en active Pending
-
2024
- 2024-05-22 JP JP2024083379A patent/JP2024103547A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519246A5 (enExample) | ||
| Withers et al. | Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program | |
| JP7034955B2 (ja) | 免疫療法向けのｔ細胞組成物 | |
| Riddell et al. | The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells | |
| Berger et al. | Adoptive transfer of virus-specific and tumor-specific T cell immunity | |
| JP2023130355A (ja) | ナイーブｔ細胞集団からのウイルスまたは他の抗原に特異的なｔ細胞の生成 | |
| JP2014514927A5 (enExample) | ||
| JP2019531722A5 (enExample) | ||
| JP2014511704A5 (enExample) | ||
| US10772914B1 (en) | EBV-specific immune cells | |
| Full et al. | T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor | |
| Liu et al. | CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals | |
| EP4458419A3 (en) | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto | |
| Stockinger et al. | CD4 T-cell memory | |
| Gary et al. | Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts | |
| Stanhope et al. | An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes | |
| Stanhope et al. | Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine | |
| CN111529697A (zh) | 调节的免疫优势疗法 | |
| JP2020506943A5 (enExample) | ||
| Nicholson et al. | Cytomegalovirus-specific T-cell therapies: current status and future prospects | |
| Foster et al. | Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy | |
| Nolte et al. | Assessment and characterization of the cytolytic T lymphocyte response against Epstein–Barr virus in patients with non-Hodgkin’s lymphoma after autologous peripheral blood stem cell transplantation | |
| JPWO2020055862A5 (enExample) | ||
| Beloki et al. | Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor–mobilized donors | |
| Liu et al. | The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine |